Cargando…

Increased leptin and A-FABP levels in relapsing and progressive forms of MS

BACKGROUND: Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive forms of MS. METHODS: Adipokine levels were measured in untreated...

Descripción completa

Detalles Bibliográficos
Autores principales: Messina, Silvia, Vargas-Lowy, David, Musallam, Alexander, Healy, Brian C, Kivisakk, Pia, Gandhi, Roopali, Bove, Riley, Gholipour, Taha, Khoury, Samia, Weiner, Howard L, Chitnis, Tanuja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829106/
https://www.ncbi.nlm.nih.gov/pubmed/24215402
http://dx.doi.org/10.1186/1471-2377-13-172
_version_ 1782291325528309760
author Messina, Silvia
Vargas-Lowy, David
Musallam, Alexander
Healy, Brian C
Kivisakk, Pia
Gandhi, Roopali
Bove, Riley
Gholipour, Taha
Khoury, Samia
Weiner, Howard L
Chitnis, Tanuja
author_facet Messina, Silvia
Vargas-Lowy, David
Musallam, Alexander
Healy, Brian C
Kivisakk, Pia
Gandhi, Roopali
Bove, Riley
Gholipour, Taha
Khoury, Samia
Weiner, Howard L
Chitnis, Tanuja
author_sort Messina, Silvia
collection PubMed
description BACKGROUND: Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive forms of MS. METHODS: Adipokine levels were measured in untreated adult relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and Healthy control (HC). Pediatric-onset MS (POMS) and pediatric healthy controls (PHC) were also assessed. Leptin and A-FABP levels were measured in serum by ELISA. Groups were compared using linear mixed-effects model. RESULTS: Excluding two patients with Body Mass Index (BMI) > 50, a significant difference in leptin level was found between RRMS and HC controlling for age (p = 0.007), SPMS and HC controlling for age alone (p = 0.002), or age and BMI (p = 0.007). A-FABP levels were higher in SPMS than HC (p = 0.007), controlling for age and BMI. Differences in A-FABP levels between POMS and PHC was observed after controlling for age (p = 0.019), but not when BMI was added to the model (p = 0.081). CONCLUSION: Leptin and A-FABP levels are highest in SPMS compared to HC, suggesting a role in pathogenesis of this disease subtype. A-FABP levels are increased in POMS patients and may play a role in the early stages of disease.
format Online
Article
Text
id pubmed-3829106
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38291062013-11-16 Increased leptin and A-FABP levels in relapsing and progressive forms of MS Messina, Silvia Vargas-Lowy, David Musallam, Alexander Healy, Brian C Kivisakk, Pia Gandhi, Roopali Bove, Riley Gholipour, Taha Khoury, Samia Weiner, Howard L Chitnis, Tanuja BMC Neurol Research Article BACKGROUND: Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive forms of MS. METHODS: Adipokine levels were measured in untreated adult relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and Healthy control (HC). Pediatric-onset MS (POMS) and pediatric healthy controls (PHC) were also assessed. Leptin and A-FABP levels were measured in serum by ELISA. Groups were compared using linear mixed-effects model. RESULTS: Excluding two patients with Body Mass Index (BMI) > 50, a significant difference in leptin level was found between RRMS and HC controlling for age (p = 0.007), SPMS and HC controlling for age alone (p = 0.002), or age and BMI (p = 0.007). A-FABP levels were higher in SPMS than HC (p = 0.007), controlling for age and BMI. Differences in A-FABP levels between POMS and PHC was observed after controlling for age (p = 0.019), but not when BMI was added to the model (p = 0.081). CONCLUSION: Leptin and A-FABP levels are highest in SPMS compared to HC, suggesting a role in pathogenesis of this disease subtype. A-FABP levels are increased in POMS patients and may play a role in the early stages of disease. BioMed Central 2013-11-11 /pmc/articles/PMC3829106/ /pubmed/24215402 http://dx.doi.org/10.1186/1471-2377-13-172 Text en Copyright © 2013 Messina et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Messina, Silvia
Vargas-Lowy, David
Musallam, Alexander
Healy, Brian C
Kivisakk, Pia
Gandhi, Roopali
Bove, Riley
Gholipour, Taha
Khoury, Samia
Weiner, Howard L
Chitnis, Tanuja
Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title_full Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title_fullStr Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title_full_unstemmed Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title_short Increased leptin and A-FABP levels in relapsing and progressive forms of MS
title_sort increased leptin and a-fabp levels in relapsing and progressive forms of ms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829106/
https://www.ncbi.nlm.nih.gov/pubmed/24215402
http://dx.doi.org/10.1186/1471-2377-13-172
work_keys_str_mv AT messinasilvia increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT vargaslowydavid increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT musallamalexander increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT healybrianc increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT kivisakkpia increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT gandhiroopali increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT boveriley increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT gholipourtaha increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT khourysamia increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT weinerhowardl increasedleptinandafabplevelsinrelapsingandprogressiveformsofms
AT chitnistanuja increasedleptinandafabplevelsinrelapsingandprogressiveformsofms